(Q34571883)

3 August 2017

1 reference

title

The role of hypoxia-activated prodrugs in cancer therapy (English)

1 reference

3 August 2017

0 references

W A Denny

1

1 reference

3 August 2017

1 September 2000

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

1

1 reference

3 August 2017

1

1 reference

3 August 2017

25-29

1 reference

Transmural Coupling of Fluid Flow in Microcirculatory Network and Interstitium in Tumors

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Therapeutic advantage of hypoxic cells in tumors: a theoretical study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Tirapazamine-cisplatin: the synergy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900006-1

7 January 2021

10.1016/S1470-2045(00)00006-1

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11905684